drugset / Trial / NCT05103241
A Phase I Mass Balance Study of [14C]GP681 in Healthy Chinese Male Volunteers
NaSingle-groupOpen-labelOther
Summary
This study is a single-center, open-label, and single-dose clinical study to evaluate the mass balance, biotransformation and pharmacokinetics of \[14C\]GP681 in healthy Chinese male volunteers, revealing the overall pharmacokinetic characteristics of GP681 in humans, and providing a reference for the rational administration.
Timeline
- Start
- 2021-10-26
- Primary completion
- 2021-11-22
- Completion
- 2021-11-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GP681 | Unknown | 40 mg | Oral |
Indications
No indication recorded.